I am Chief Scientific Officer at Psylo; a biotech start-up developing next-generation psychedelic medicines for the treatment of mental illness. Psylo's research laboratories are co-located at UNSW, where I am an adjunct member of the School of Chemistry.
My research includes the design of new methods for imaging the brain, as well as the development of new neurological and neuropsychiatric drugs for the treatment of central nervous system diseases including ALS, depression, pain, and substance use disorders.
I also collaborate with local and international government laboratories to improve our understanding of the chemistry, pharmacology, and toxicology of "new psychoactive substances" such as synthetic cannabinoids, cathinones, and opioids.
Experience
-
2022–presentChief Scientific Officer, Psylo
-
2022–presentAdjunct, UNSW
-
2018–2022Team Leader in Medicinal Chemistry, The University of Sydney
-
2017–2017Research Scientists, Stanford University
-
2014–2016Postdoctoral Research Fellow, Stanford University
-
2012–2013Postdoctoral Research Associate, The Brain and Mind Research Institute
Education
-
2011The University of Sydney, PhD
- Sydney, Australia
- Website
- @samuel_b_phd
- Article Feed
- samuel.banister@sydney.edu.au
- ORCID
- Joined
